GAMBACORTI PASSERINI, CARLO
 Distribuzione geografica
Continente #
NA - Nord America 22491
EU - Europa 7630
AS - Asia 1867
Continente sconosciuto - Info sul continente non disponibili 34
SA - Sud America 24
AF - Africa 21
OC - Oceania 9
Totale 32076
Nazione #
US - Stati Uniti d'America 22093
DE - Germania 1950
IT - Italia 1780
SE - Svezia 1361
CN - Cina 1334
UA - Ucraina 974
GB - Regno Unito 440
CA - Canada 395
IE - Irlanda 291
FI - Finlandia 196
VN - Vietnam 179
TR - Turchia 169
FR - Francia 137
RU - Federazione Russa 123
DK - Danimarca 117
IN - India 106
BE - Belgio 81
AT - Austria 54
NL - Olanda 42
EU - Europa 32
BG - Bulgaria 30
IR - Iran 23
KR - Corea 18
JP - Giappone 17
RO - Romania 12
CH - Svizzera 11
BR - Brasile 10
CL - Cile 10
MU - Mauritius 9
GR - Grecia 8
AU - Australia 7
MY - Malesia 7
NO - Norvegia 5
SC - Seychelles 5
CZ - Repubblica Ceca 4
ZA - Sudafrica 3
A2 - ???statistics.table.value.countryCode.A2??? 2
BD - Bangladesh 2
EC - Ecuador 2
EG - Egitto 2
KW - Kuwait 2
MK - Macedonia 2
NZ - Nuova Zelanda 2
PT - Portogallo 2
SA - Arabia Saudita 2
SK - Slovacchia (Repubblica Slovacca) 2
TH - Thailandia 2
AL - Albania 1
AM - Armenia 1
AR - Argentina 1
BA - Bosnia-Erzegovina 1
EE - Estonia 1
ES - Italia 1
HK - Hong Kong 1
HN - Honduras 1
ID - Indonesia 1
IQ - Iraq 1
LK - Sri Lanka 1
LT - Lituania 1
MA - Marocco 1
MD - Moldavia 1
MX - Messico 1
MZ - Mozambico 1
PE - Perù 1
PL - Polonia 1
PR - Porto Rico 1
SI - Slovenia 1
TW - Taiwan 1
Totale 32076
Città #
Ann Arbor 6052
Woodbridge 2694
Fairfield 2264
Houston 1573
Chandler 1395
Frankfurt am Main 1358
Wilmington 1302
Jacksonville 1033
Ashburn 968
Seattle 887
Milan 855
Dearborn 790
Cambridge 771
Princeton 558
Nanjing 311
Dublin 290
Lawrence 246
Altamura 245
Göttingen 188
Beijing 184
Lachine 172
San Diego 134
Guangzhou 105
Lissone 101
Andover 97
Nanchang 94
Dong Ket 91
Shenyang 88
Toronto 88
Ottawa 82
Fremont 80
Brussels 79
Boardman 75
Hebei 68
Fürstenwalde 65
Tianjin 59
Jiaxing 56
Jinan 48
Vienna 47
Falls Church 46
Norwalk 46
Kocaeli 45
Changsha 43
Mountain View 42
Kunming 40
Redmond 37
Edmonton 35
Huizen 32
Hangzhou 28
Hefei 27
Kiev 26
Zhengzhou 24
Shanghai 23
London 22
Ningbo 20
Plovdiv 20
Helsinki 19
Chicago 16
Nürnberg 16
Detroit 15
Rome 15
San Mateo 15
Leawood 14
Sacramento 14
Los Angeles 13
Monmouth Junction 13
Pavia 13
Daejeon 12
Taizhou 12
University Park 12
Fuzhou 11
Verona 11
Auburn Hills 10
Lanzhou 10
Zanjan 10
Bologna 9
Boston 9
Taiyuan 9
Changchun 8
Duncan 8
Torino 8
Washington 8
Laurel 7
Monza 7
Mumbai 7
Perugia 7
Solbiate Olona 7
Bangalore 6
Haikou 6
Kuala Lumpur 6
Montréal 6
Athens 5
Cinisello Balsamo 5
Grafing 5
Lodi 5
Motta Di Livenza 5
San Francisco 5
Wuhan 5
Baotou 4
Brindisi 4
Totale 26561
Nome #
Characterization of intra-host SARS-CoV-2 variants improves phylogenomic reconstruction and may reveal functionally convergent mutations 341
De novo UBE2A mutations are recurrently acquired during chronic myeloid leukemia progression and interfere with myeloid differentiation pathways 340
A bioinformatics procedure to identify and annotate somatic mutations in whole-exome sequencing data 312
Lorlatinib treatment elicits multiple on- and off-target mechanisms of resistance in ALK-driven cancer 309
Wiskott–Aldrich syndrome protein (WASP) is a tumor suppressor in T cell lymphoma 292
VERSO: a comprehensive framework for the inference of robust phylogenies and the quantification of intra-host genomic diversity of viral samples 292
Acute myeloid leukaemia niche regulates response to L-asparaginase 275
RNA-seq is a valuable complement of conventional diagnostic tools in newly diagnosed AML patients 268
BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene 266
Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib 263
Age and dPCR can predict relapse in CML patients who discontinued imatinib: The ISAV study 263
Imatinib Long-Term Effects Study: Global Independent Assessment of Imatinib in Chronic Myeloid Leukemia: Results At 8 Years 253
VERSO:A COMPREHENSIVE FRAMEWORK FOR THE INFERENCE OF ROBUST PHYLOGENIES AND THE QUANTIFICATION OF INTRA-HOST GENOMIC DIVERSITY OF VIRAL SAMPLES 249
The Risk of Relapse in CML Patients Who Discontinued imatinib Can Be Predicted Based on Patients Age and the Results of dPCR Analysis 245
Long-term efficacy and safety of crizotinib in relapsed ALK positive lymphoma patients: clinical and biological correlates 244
OncoScore: A novel, Internet-based tool to assess the oncogenic potential of genes 243
Chronic myeloid leukemia: Second-line drugs of choice 237
Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency 235
Erratum: OncoScore: a novel, Internet-based tool to assess the oncogenic potential of genes 234
A computational procedure to identify and annotate somatic mutations in next-generation sequencing data 233
ETNK1 MUTATIONS INCREASE MITOCHONDRIAL ACTIVITY AND PROMOTE DNA DAMAGE THROUGH ROS PRODUCTION 233
An Imatinib–non-responsive patient with an ABL Leu387Trp mutation achieves cytogenetic and molecular response under bosutinib: Case report and biological characterization 227
WHOLE-EXOME SEQUENCING OF A PHILADELPHIA NEGATIVE CHRONIC MYELOID LEUKEMIA PATIENT THROUGH THE EXON-CAPTURE TECHNIQUE 226
Imatinib long term effects study: three years of follow-up and assessment 219
ETNK1 mutations promote ROS production and DNA damage through increased mitochondrial activity 214
SETBP1 induces transcription of a network of development genes by acting as an epigenetic hub 213
Characterization of compound 584, an Abl kinase inhibitor with lasting effects 212
Three novel patients derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors 203
A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib 202
In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl(+) neoplastic cells 197
Decitabine treatment for an unusual case of atypical chronic myeloid leukemia (aCML) with a concomitant chronic lymphocytic leukemia (CLL) 192
Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition 188
Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphoma 185
Recurrent SETBP1 mutations in atypical chronic myeloid leukemia 176
BCR-ABL nuclear entrapment kills human CML cells: ex vivo study on 35 patients with the combination of imatinib mesylate and leptomycin B 175
Response to 'D276G mutation is associated with a poor prognosis in imatinib mesylate-resistant chronic myeloid leukemia patients' by Leguay et al 175
Synthesis, structure-activity relationship and crystallographic studies of 3-substituted indolin-2-one RET inhibitors 175
Choosing the right TKI for chronic myeloid leukemia: when the truth lies in "long-term" safety and efficacy 174
In vitro and in vivo identification of ABCB1 as an efflux transporter of bosutinib 174
Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients 172
ETNK1 mutations in atypical chronic myeloid leukemia induce a mutator phenotype that can be reverted with phosphoethanolamine 171
FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia 169
Identification of novel point mutations in splicing sites integrating whole-exome and RNA-seq data in myeloproliferative diseases 166
Tyrosine kinase inhibitor interruptions, discontinuations and switching in patients with chronic-phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY 163
Gene expression signature of non-involved lung tissue associated with survival in lung adenocarcinoma patients 162
Evidence of ETNK1 Somatic Variants in Atypical Chronic Myeloid Leukemia 162
CEQer: A Graphical Tool for Copy Number and Allelic Imbalance Detection from Whole-Exome Sequencing Data 160
Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase 160
ALK inhibitors for clinical use in cancer therapy 159
Structural insights into the ATP binding pocket of the anaplastic lymphoma kinase by site-directed mutagenesis, inhibitor binding analysis, and homology modeling 158
Highly sensitive mutations detection in BCR-ABL positive leukemia prior and during imatinib treatment 158
Treatment efficacy and resistance mechanisms using the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma 158
Mitochondrial Hyperactivation and Enhanced ROS Production are Involved in Toxicity Induced by Oncogenic Kinases Over-Signaling 156
Synthesis and biological evaluation of benzo[4,5]imidazo[1,2-c]pyrimidine and benzo[4,5]imidazo[1,2-a]pyrazine derivatives as anaplastic lymphoma kinase inhibitors 155
NPM/ALK binds and phosphorylates the RNA/DNA-binding protein PSF in anaplastic large-cell lymphoma 154
Abstract 902: In vitro andin vivocharacterization of resistance to lorlatinib treatment in ALK mutated cancers 154
Concomitant BCORL1 and BRAF Mutations in Vemurafenib-Resistant Melanoma Cells 154
Oncogenic fusion tyrosine kinases as molecular targets for anti-cancer therapy 153
Reply to P. Laneuville et al 153
Recurrent ETNK1 mutations in atypical chronic myeloid leukemia 152
Erratum: Identification of 4-Phenoxyquinoline Based Inhibitors for L1196M Mutant of Anaplastic Lymphoma Kinase by Structure-Based Design (Journal of Medicinal Chemistry (2017) 60:22 (9205-9221) DOI: 10.1021/acs.jmedchem.7b01039) 151
ERG deregulation induces PIM1 over-expression and aneuploidy in prostate epithelial cells 149
Inhibition of RET tyrosine kinase by SU5416 148
A fatal case of TEMPI syndrome, refractory to proteasome inhibitors and autologous stem cell transplantation 148
Expression, purification, and inhibition of human RET tyrosine kinase 147
Integrated Genomic, Functional and Prognostic Characterization of Atypical Chronic Myeloid Leukemia (aCML) in a Cohort of 43 Patients 147
Phase two study of crizotinib in patients with anaplastic lymphoma kinase (ALK) positive anaplastic large cell lymphoma relapsed/refractory to chemotherapy 147
Crizotinib-Resistant NPM-ALK Mutants Confer Differential Sensitivity to Unrelated Alk Inhibitors 146
Design, synthesis, and biological activity of urea derivatives as anaplastic lymphoma kinase inhibitors 146
A New BCR-ABL1 Mutation (L248R) Is Highly Resistant to Imatinib, Bosutinib, Nilotinib and Dasatinib, but Can Be Inhibited by AP-24534 and DCC-2036 146
Killer immunoglobulin-like receptors can predict TKI treatment-free remission in chronic myeloid leukemia patients 146
Evidence for D276G and L364I Bcr-Abl mutations in Ph plus leukaemic cells obtained from patients resistant to Imatinib 143
CML Patients Present Additional Mutations in Cancer Related Genes When Tested At Diagnosis 143
Imatinib discontinuation in chronic myeloid leukaemia patients with undetectable BCR-ABL transcript level: A systematic review and a meta-analysis 143
Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias 142
Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants 142
The achievement of durable complete cytogenetic remission in late chronic and accelerated phase patients with CML treated with Imatinib mesylate predicts for prolonged response at 6 years 141
Recurrent KIT D816V Mutation in Atypical Chronic Myeloid Leukemia 138
A rapid method for the purification of wild-type and V804M mutant ret catalytic domain: A tool to study thyroid cancer 137
Integrated Analysis of Whole-Exome Sequencing and Micrornas Expression in Blast Crisis Transformation of Chronic Myeloid Leukemia 137
ABL INHIBITOR BMS354825 BINDING MODE IN ABELSON KINASE REVEALED BY MOLECULAR DOCKING STUDIES 137
Personal history and quality of life in chronic myeloid leukemia patients: a cross-sectional study using narrative medicine and quantitative analysis 137
Clinical Benefit of Lenzilumab in Cases of Coronavirus Disease 2019 136
Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis 136
Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL 134
Reversal of microRNA-150 silencing disadvantages crizotinib-resistant NPM-ALK(+) cell growth 133
Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes 133
Differences among young adults, adults and elderly chronic myeloid leukemia patients 133
Whole-Exome Sequencing Data - Identifying Somatic Mutations 133
Integrated Genomic, Functional, and Prognostic Characterization of Atypical Chronic Myeloid Leukemia 133
BCR AND BCR-ABL REGULATION DURING MYELOID DIFFERENTIATION IN HEALTHY DONORS AND CHRONIC PHASE-BLAST CRISIS CML PATIENTS 132
Are Chronic Myeloid Leukemia Patients More at Risk for Second Malignancies? A Population-based Study 131
The ALK gene, an attractive target for inhibitor development 131
FusionAnalyser: a new graphical, event-driven tool for fusion rearrangements discovery 131
Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK 131
Anaplastic lymphoma kinase and its signalling molecules as novel targets in lymphoma therapy 130
Valproic acid enhances bosutinib cytotoxicity in colon cancer cells 130
Chronic myeloid leukemia: Reminiscences and dreams 129
Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation 128
Autoimmune hepatitis presenting as imatinib toxicity: description of a case and of therapeutic alternatives 128
Totale 18036
Categoria #
all - tutte 51896
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 51896


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2017/2018293 0000 00 0141 53273438
2018/20193206 47488728 70284 225211 378406719703
2019/20207595 828512526616 695854 1095607 733473489167
2020/20217245 335309900755 604687 728665 640637450535
2021/20223987 314389490265 264354 212225 200300326648
2022/20235389 8581903562552 464927 1230 0000
Totale 33577